pI: 4.9652 |
Length (AA): 247 |
MW (Da): 28101 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 244 | 2amy (A) | 4 | 246 | 52.00 | 0 | 1 | 1.69 | -1.78 |
4 | 242 | 2fue (A) | 13 | 253 | 51.00 | 0 | 1 | 1.74 | -1.83 |
4 | 245 | 2i54 (A) | 4 | 245 | 94.00 | 0 | 1 | 2.22436 | -2.12 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | amastigotes. | Fernandes MC |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127648)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G45790 | phosphomannomutase |
Babesia bovis | BBOV_IV009850 | phosphomannomutase, putative |
Brugia malayi | Bm1_38705 | phosphomannomutase 2 |
Candida albicans | CaO19.2937 | phosphomannomutase that can functionally substitute for S. cerevisiae SEC53 (YFL045C) |
Candida albicans | CaO19.10454 | phosphomannomutase that can functionally substitute for S. cerevisiae SEC53 (YFL045C) |
Caenorhabditis elegans | CELE_F52B11.2 | Protein F52B11.2, isoform B |
Cryptosporidium hominis | Chro.40115 | hypothetical protein |
Cryptosporidium parvum | cgd4_960 | phosphomannomutase |
Dictyostelium discoideum | DDB_G0272781 | phosphomannomutase B |
Dictyostelium discoideum | DDB_G0279289 | hypothetical protein |
Drosophila melanogaster | Dmel_CG10688 | CG10688 gene product from transcript CG10688-RA |
Echinococcus granulosus | EgrG_000927400 | phosphomannomutase |
Entamoeba histolytica | EHI_179810 | phosphomannomutase, putative |
Echinococcus multilocularis | EmuJ_000927400 | phosphomannomutase |
Homo sapiens | ENSG00000140650 | phosphomannomutase 2 |
Homo sapiens | ENSG00000100417 | phosphomannomutase 1 |
Leishmania braziliensis | LbrM.35.2180 | phosphomannomutase, putative |
Leishmania donovani | LdBPK_362070.1 | phosphomannomutase, putative |
Leishmania infantum | LinJ.36.2070 | phosphomannomutase, putative |
Leishmania major | LmjF.36.1960 | phosphomannomutase, putative |
Leishmania mexicana | LmxM.36.1960 | phosphomannomutase, putative |
Loa Loa (eye worm) | LOAG_11718 | phosphomannomutase 2 |
Mus musculus | ENSMUSG00000022711 | phosphomannomutase 2 |
Mus musculus | ENSMUSG00000022474 | phosphomannomutase 1 |
Neospora caninum | NCLIV_016330 | phosphomannomutase 2, putative |
Oryza sativa | 4337437 | Os04g0682300 |
Onchocerca volvulus | OVOC4799 | Putative phosphomannomutase |
Plasmodium berghei | PBANKA_0501700 | phosphomannomutase, putative |
Plasmodium falciparum | PF3D7_1017400 | phosphomannomutase, putative |
Plasmodium knowlesi | PKNH_0601600 | phosphomannomutase, putative |
Plasmodium vivax | PVX_001740 | phosphomannomutase, putative |
Plasmodium yoelii | PY00199 | Eukaryotic phosphomannomutase |
Saccharomyces cerevisiae | YFL045C | phosphomannomutase SEC53 |
Schistosoma japonicum | Sjp_0081430 | ko:K01840 phosphomannomutase [EC5.4.2.8], putative |
Schistosoma japonicum | Sjp_0081440 | IPR005002,Eukaryotic phosphomannomutase,domain-containing |
Schistosoma mansoni | Smp_087860 | phosphomannomutase |
Schmidtea mediterranea | mk4.001409.00 | Probable phosphomannomutase |
Schmidtea mediterranea | mk4.000173.04 | Phosphomannomutase |
Trypanosoma brucei gambiense | Tbg972.10.7890 | phosphomannomutase, putative |
Trypanosoma brucei | Tb927.10.6440 | phosphomannomutase |
Trypanosoma congolense | TcIL3000_10_5500 | phosphomannomutase, putative |
Trypanosoma cruzi | TcCLB.510187.480 | phosphomannomutase, putative |
Toxoplasma gondii | TGME49_239710 | phosphomannomutase |
Theileria parva | TP01_0785 | phosphomannomutase, putative |
Trichomonas vaginalis | TVAG_111700 | phosphomannomutase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.6440 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.6440 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.6440 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.6440 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_F52B11.2 | Caenorhabditis elegans | slow growth | wormbase |
YFL045C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_0501700 | Plasmodium berghei | Dispensable | plasmo |
TGME49_239710 | Toxoplasma gondii | Probably essential | sidik |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
viability (PATO:0000169) | absent (PATO:0000462) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from loss-of-function mutant phenotype (ECO:0000016) | Leishmania mexicana | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | L. mexicana DeltaPMM are largely devoid of all known Man-containing glycoconjugates and are unable to establish an infection in mouse macrophages or the living animal. | References: | 11689705 | |
viability (PATO:0000169) | absent (PATO:0000462) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | L. mexicana DeltaPMM are largely devoid of all known Man-containing glycoconjugates and are unable to establish an infection in mouse macrophages or the living animal. | References: | 11689705 | |
viability (PATO:0000169) | absent (PATO:0000462) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | host (GO:0018995) | Leishmania mexicana | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | L. mexicana DeltaPMM are largely devoid of all known Man-containing glycoconjugates and are unable to establish an infection in mouse macrophages or the living animal. | References: | 11689705 | |
viability (PATO:0000169) | absent (PATO:0000462) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from loss-of-function mutant phenotype (ECO:0000016) | Leishmania major | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | L. major PMM knockouts are avirulent. | References: | 16963079 | |
viability (PATO:0000169) | absent (PATO:0000462) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania major | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | L. major PMM knockouts are avirulent. | References: | 16963079 | |
viability (PATO:0000169) | absent (PATO:0000462) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | host (GO:0018995) | Leishmania major | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | L. major PMM knockouts are avirulent. | References: | 16963079 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.2
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | phosphomannomutase 2 | Compounds | References |
2 literature references were collected for this gene.